Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDUFA IV Takes Shape: A Catalogue Of Draft Commitments

Executive Summary

More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.


Related Content

Will Senate User-Fee Package Be Smooth Sailing Despite Add-Ons?
The Patient Perspective: Upcoming US FDA Device Center Studies Put Device-Users In Front Seat
Senate, House Panels Release Clean Device User-Fee Discussion Draft
FDA Emphasizes Pre-Submissions For Neuro Devices
Trump Budget: FDA-Regulated Firms Should Pay 'Their Share' In User Fees
Device User-Fee Agreement Gets A Senate Hearing
US FDA Plans New Office Of Patient Affairs
Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations
Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says
Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts